Nagai, Kozo, Ochi, Toshiki, Fujiwara, Hiroshi, An, Jun, Shirakata, Toshiaki, Mineno, Junichi, Kuzushima, Kiyotaka, Shiku, Hiroshi, Melenhorst, J. Joseph, Gostick, Emma, Price, David ![]() |
Abstract
Aurora kinase A (AURKA) is overexpressed in leukemias. Previously, we demonstrated that AURKA-specific CD8+ T cells specifically and selectively lysed leukemia cells, indicating that AURKA is an excellent target for immunotherapy. In this study, we examined the feasibility of adoptive therapy using redirected T cells expressing an HLA-A*0201–restricted AURKA207-215-specific T-cell receptor (TCR). Retrovirally transduced T cells recognized relevant peptide-pulsed but not control target cells. Furthermore, TCR-redirected CD8+ T cells lysed AURKA-overexpressing human leukemic cells in an HLA-A*0201–restricted manner, but did not kill HLA-A*0201+ normal cells, including hematopoietic progenitors. In addition, AURKA207-215-specific TCR-transduced CD4+ T cells displayed target-responsive Th1 cytokine production. Finally, AURKA207-215-specific TCR-transduced CD8+ T cells displayed antileukemia efficacy in a xenograft mouse model. Collectively, these data demonstrate the feasibility of redirected T cell–based AURKA-specific immunotherapy for the treatment of human leukemia.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine Systems Immunity Research Institute (SIURI) |
Subjects: | Q Science > QH Natural history > QH426 Genetics R Medicine > RC Internal medicine |
Publisher: | American Society of Hematology |
ISSN: | 0006-4971 |
Last Modified: | 09 Nov 2022 08:26 |
URI: | https://orca.cardiff.ac.uk/id/eprint/42800 |
Citation Data
Cited 18 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
![]() |
Edit Item |